Sonoma Pharmaceuticals (NASDAQ:SNOA) Stock Crosses Above Two Hundred Day Moving Average – Here’s What Happened

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $1.78 and traded as high as $2.60. Sonoma Pharmaceuticals shares last traded at $2.55, with a volume of 19,093 shares.

Sonoma Pharmaceuticals Price Performance

The firm’s fifty day moving average is $2.82 and its 200-day moving average is $1.78. The firm has a market cap of $3.41 million, a price-to-earnings ratio of -0.51 and a beta of 1.43.

Hedge Funds Weigh In On Sonoma Pharmaceuticals

A hedge fund recently bought a new stake in Sonoma Pharmaceuticals stock. Ground Swell Capital LLC acquired a new stake in shares of Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 10,400 shares of the company’s stock, valued at approximately $32,000. Ground Swell Capital LLC owned approximately 1.08% of Sonoma Pharmaceuticals as of its most recent SEC filing. 1.95% of the stock is currently owned by institutional investors and hedge funds.

About Sonoma Pharmaceuticals

Sonoma Pharmaceuticals, Inc, develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis.